➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
McKinsey
Baxter
Mallinckrodt
Harvard Business School

Last Updated: October 18, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR LATANOPROSTENE BUNOD

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Latanoprostene Bunod

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01895972 ↗ A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension Unknown status Bausch & Lomb Incorporated Phase 3 2013-07-01 The objective of this study is to demonstrate the clinical safety of latanoprostene bunod 0.024% once daily (QD) over a 1-year treatment period.
NCT01895985 ↗ Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers Completed Bausch & Lomb Incorporated Phase 1 2013-07-01 The objective of this study is to evaluate the effect of latanoprostene bunod dosed once daily (QD) in reducing intraocular pressure (IOP) measured over a 24-hour period in healthy subjects.
NCT03931317 ↗ Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity Recruiting Bausch & Lomb Incorporated N/A 2018-12-03 The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye.
NCT03931317 ↗ Study Comparing the Effects of Latanoprostene Bunod and Timolol on Retinal Blood Vessel Density and Visual Acuity Recruiting University of California, San Diego N/A 2018-12-03 The purpose of this research study is to compare the effect of Latanoprostene Bunod and Timolol on eye pressure and blood vessels of the back of the eye.
NCT03949244 ↗ Nailfold Capillary Blood Flow With Latanoprost Bunod Not yet recruiting Icahn School of Medicine at Mount Sinai Phase 4 2019-05-01 The purpose of this study is to look at the relationship of small blood vessels irregularities observed with an imaging system called video nailfold capillaroscopy in people with primary open-angle glaucoma. Nailfold capillaroscopy (NFC) is a video camera with a magnifying lens used for studying the movement of blood in small blood vessels. It is simple, safe and does not penetrate the skin. The skin fold that is at the tip of the finder is called the "nailfold". NFC has been used to assess blood vessel narrowing in patients with glaucoma.
NCT04140279 ↗ A Study to Evaluate the Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Participants With Ocular Hypertension Not yet recruiting Bausch & Lomb Incorporated Phase 4 2019-11-15 The primary objective of this study is to determine the effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% (a single dose and 7 days of once daily [QD] dosing) on 2 aspects of aqueous humor (AqH) dynamics (episcleral venous pressure [EVP] and outflow facility) in participants with ocular hypertension (OHT).
NCT04981886 ↗ Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma Not yet recruiting Salus University Phase 4 2021-08-01 Glaucoma is the second leading cause of blindness and the first leading cause of irreversible vision loss worldwide. The intraocular pressure (IOP) is the only modifiable risk factor for all the spectrum of glaucoma. Reducing IOP in glaucoma increases the likelihood of preventing progression of the disease and preserving the quality of life of the patient. Although prostaglandin analogs (PGAs) and prostamides (PMs) are de facto first-line treatment options for managing glaucoma, it is a common clinical experience to see their treatment effects plateau to a level beyond which no clinically significant IOP reduction is likely. It is also common to find minimal IOP treatment effects in the following conditions: patients with normal tension glaucoma (NTG), patients with thicker central corneal thickness (CCT), and patients with higher levels of corneal hysteresis (CH). CH is a possible proxy for the ability of the scleral tissue around the optic nerve to dissipate energy away from the optic nerve fibers. Netarsudil, a rho-kinase inhibitor was recently approved by the FDA for the treatment of glaucoma and ocular hypertension. There is a paucity of research on the efficacy of netarsudil in patients with NTG, thicker CCT, and higher levels of CH. This study aims to investigate the above issues by evaluating the efficacy of netarsudil and bimatoprost in subjects with NTG, thicker corneas, and higher levels of CH. Hypotheses - Netarsudil will have non-inferior efficacy compared to Bimatoprost in treating NTG. - Corneal thickness and corneal hysteresis will reduce the efficacy of netarsudil similar to bimatoprost in NTG. - Netarsudil will change corneal thickness and corneal hysteresis similar to bimatoprost in NTG.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Latanoprostene Bunod

Condition Name

Condition Name for Latanoprostene Bunod
Intervention Trials
Ocular Hypertension 2
Glaucoma 1
OHT - Ocular Hypertension 1
OAG - Open-Angle Glaucoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Latanoprostene Bunod
Intervention Trials
Ocular Hypertension 3
Hypertension 3
Glaucoma, Open-Angle 3
Glaucoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Latanoprostene Bunod

Trials by Country

Trials by Country for Latanoprostene Bunod
Location Trials
United States 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Latanoprostene Bunod
Location Trials
New York 2
New Jersey 2
Minnesota 1
California 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Latanoprostene Bunod

Clinical Trial Phase

Clinical Trial Phase for Latanoprostene Bunod
Clinical Trial Phase Trials
Phase 4 3
Phase 3 1
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Latanoprostene Bunod
Clinical Trial Phase Trials
Not yet recruiting 3
Completed 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Latanoprostene Bunod

Sponsor Name

Sponsor Name for Latanoprostene Bunod
Sponsor Trials
Bausch & Lomb Incorporated 4
Salus University 1
Icahn School of Medicine at Mount Sinai 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Latanoprostene Bunod
Sponsor Trials
Industry 4
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Merck
Mallinckrodt
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.